p21 plays an important role in modulating cell cycle control, inducing apoptosis, and inhibiting cell growth, subsequently affecting cancer risk. We investigated the association between two putatively functional single-nucleotide polymorphisms (SNPs) of p21 (p21 C98A and p21 C70T) among 1282 patients diagnosed with incident squamous cell carcinoma of the head and neck (SCCHN) and risk of second primary malignancy (SPM) in an ongoing molecular epidemiology study. We used Log-rank test and Cox proportional hazard models to assess the association of these two SNPs with SPM-free survival and SPM risk. We found that patients with either p21 variant genotypes of the two polymorphisms had a significantly reduced SPM-free survival compared with patients with either p21 wild-type homozygous genotypes (Log-rank test, P 5 0.0016). Compared with patients having the p21 98 CC and p21 70 CC genotypes, the patients having p21 98 CA/AA and p21 70 CT/TT variant genotypes had a significantly greater risk of developing SPM, respectively, [hazard ratio (HR) 5 1.80, 95% CI 5 1.14-2.82 for p21 C98A and HR 5 1.82, 95% confidence interval (CI) 5 1.16-2.85 for p21 C70T]. Moreover, after combining the variant genotypes of two SNPs, patients with variant genotypes had a significantly moderately increased risk for SPM compared with patients with no variant genotypes (HR 5 2.00, 95% CI 5 1.26-3.00), and the risk was particularly pronounced in several subgroups. Our results support an increased risk of SPM after index SCCHN with both p21 polymorphisms individually and in combination.
Introduction
Squamous cell carcinoma of the head and neck (SCCHN) including the oral cavity, oropharynx, hypopharynx and larynx is the fifth most common type of cancer. Although the overall incidence rate of SCCHN has decreased in the recent decade in the USA (1, 2) , the moderately low survival, high recurrence rates and high second primary malignancy (SPM) rates are still a clinical burden (3, 4) .
The cumulative incidence of SPMs in SCCHN patients varies between 10-20% (4) (5) (6) . Although tobacco and alcohol exposure (7) (8) (9) and cancer treatment (10, 11) have been found to be associated with the risk of SPMs, these risk factors do not account for the development of all SPMs. It is probably that interindividual variation in genetic susceptibility to SPMs among SCCHN patients also contributes to the development of SPMs (4) . In addition, several research groups including ours have reported that inherited genetic factors are associated with the risk of developing a SPM after an index SCCHN (12) (13) (14) (15) (16) (17) .
Alterations in genes involved in cell cycle control frequently result in dysregulated cellular proliferation; specifically, genes associated with the regulation of the G 1 checkpoint in the cell cycle are frequently altered in cancer cells (18) . For instance, cyclins and cyclin-dependent kinases (CDKs) form protein complexes to modulate cell proliferation through the cell cycle control, and CDK inhibitors inhibit kinase activities of the complexes and block transitions of the cell cycle (19) (20) (21) . The p21 (also known as Waf1/Cip1/CDKN1A) protein is one of CDK inhibitors that are essential for cellular growth, differentiation and apoptosis (22) .
p21, a putative tumor suppressor gene, is located on chromosome 6p21.2 and encodes a 21 kDa protein (23) that belongs to the CDKinteracting proteins/kinase inhibitor proteins family including p27 (22) and p57 (24, 25) . Overexpression of p21 inhibits proliferation in mammalian cells and has been found to inhibit all cyclin-CDK complexes, indicating that it is a universal cyclin-CDK inhibitor (22) . The CDK-interacting proteins/kinase inhibitor proteins proteins share some common sequence motifs that mediate interaction between CDK inhibitors and cyclin-CDK complexes (26, 27) . p21 is known to be directly regulated by the tumor suppressor p53 and is considered to be one of the most important and potent effector molecules of p53. The p53 protein directly activates p21 expression by binding its promoter (28) . Hence, in human cancers, inactivation of p53 will also lead to decreased levels of p21.
Since p21 expression is one of the most prominent markers for the functional activity of p53, many studies have analyzed p21 expression in different types of human cancer but the results are conflicting. In some reports, the lack of p21 was indeed shown to correlate with tumor progression and negative prognosis, as reported, for example, for small-cell lung (29) , colorectal (30) , cervical (31) and head and neck cancers (32) . In some cases, however, p21 expression was concluded to have no prognostic value (33) (34) (35) (36) (37) . Given the functional importance of p21 in critical p53 pathway, genetic alteration of p21 could be associated with prognosis in SCCHN patients.
We previously reported that each or in combination of two putatively functional polymorphisms of p21 were significantly associated with risk of SCCHN (38) . One is a common single-nucleotide polymorphism, p21 C98A in exon 2, which causes a non-synonymous serine-to-arginine substitution at codon 31. Another is the p21 C70T within the 3# untranslated region, which causes a single C-to-T substitution 20 nt downstream of the stop codon at exon 3. However, the role of p21 polymorphisms in the etiology of SPM after index SCCHN has not been investigated. Because both common single-nucleotide polymorphisms are thought to alter p21 function, the two polymorphisms could also contribute to the risk of SPM among SCCHN patients.
To test whether each or in combination of the two p21 polymorphisms is associated with the risk of SPM within a cohort of 1282 patients initially recruited with incident index SCCHN, we hypothesize that each and, more probably, in combination of the two p21 polymorphisms confer an increased risk of SPM for SCCHN patients.
Materials and methods
Study subjects A cohort of 1667 patients with incident SCCHN, who were newly diagnosed, histopathologically confirmed, and untreated squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx or larynx were consecutively recruited from May 1995 to January 2007 at The University of Texas M. D. Anderson Cancer Center as part of an ongoing molecular epidemiologic study, which has been described previously elsewhere (39, 40 patients having distant metastases on presentation were not recruited). Patients with any prior cancer history excepting non-melanoma skin cancer were not recruited. Also, patients with primary sinonasal tumors, salivary gland tumors, cervical metastases of unknown origin or tumors outside the upper aerodigestive tract were not recruited. Approximately 95% of contacted patients consented to enrollment in the study. Blood samples for p21 genotyping data were not available for some patients recruited early in the study, and these patients were excluded from this genotype and SPM analysis, as were patients without follow-up or who underwent only palliative treatment. Consequently, 1282 patients were available for this study of SPM risk.
Data collection
Patients were monitored through their treatment and post-treatment course with regularly scheduled clinical and radiographic examinations. SPMs were distinguished from local recurrences based on modified criteria of Warren et al. (41) . Second lesions with different histopathologic type and/or occurring .5 years following treatment for the primary tumor and/or clearly separated by normal epithelium based on clinical and radiographic assessment were considered as SPM. If there was discrepancy or differing opinion regarding the origin of the tumor, the second lesion was classified as a local recurrence rather than an SPM. Pulmonary lesions were considered as SPM if they had a nonsquamous histology or if they were isolated squamous lesions .5 years from initial SCCHN and felt to be SPM by the thoracic oncologist and thoracic surgeon. SPMs were then classified as tobacco-associated sites (oral cavity, oropharynx, larynx, hypopharynx, esophagus, lung or bladder) and nontobacco-associated sites.
Clinical data were obtained at initial presentation and through follow-up examinations and included overall stage at presentation of the index tumor, site of the index tumor and treatment. Index cancer stage was then dichotomized into the early stage (I/II) and late stage (III/IV). We also grouped treatment into four categories: surgery only, surgery with radiotherapy and/ or chemotherapy, radiotherapy only and radiotherapy plus chemotherapy. We subsequently dichotomize treatment into those with DNA damaging agents (radiation and/or chemotherapy) and those without (surgery only). All patients completed at presentation an epidemiological questionnaire including data on alcohol and smoking status. Drinking status was categorized as 'ever-drinkers' (those who had drunk at least one alcoholic beverageper day for at least 1 year during their lifetime) and 'never-drinkers' (those who never had such a pattern of drinking). Smoking status was categorized as 'ever-smokers' (those who had smoked at least 100 cigarettes in their lifetime) and 'never-smokers' (those who had smoked ,100 cigarettes in their lifetime).
p21 genotyping
We extracted genomic DNA from the buffy-coat fraction of the blood samples using a DNA Blood Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions for genotyping p21 polymorphisms. The methods for genotyping of the polymorphisms have been described previously (38) . We performed the polymerase chain reactions and evaluated the results without knowing the subjects with SPM or without SPM. At least 10% of the random samples were retested, and the results were 100% concordant.
Statistical analysis SPM occurrence was the primary endpoint of the study. The Student's t-test was used to compare the mean age and follow-up time of the patients who developed a second primary cancer and those who did not. The differences in ethnicity, sex, smoking and alcohol status, tumor site, tumor stage, treatment, genotype distributions and allele frequencies between the two groups were evaluated using the chi-squared test. Time-to-event was calculated from the date of diagnosis of the index SCCHN to the date of SPM occurrence. Patients who were not known to have an event at the date of last contact or who died were censored. The associations between individual epidemiological risk factors, clinical characteristics, including tumor site, staging and treatment variables, and time to the occurrence of the SPMs were initially assessed using univariate Cox proportional hazards regression models. The data were consistent with the assumptions of the Cox proportional hazards regression model from the examination of Kaplan-Meier survival curves and log-minus-log survival plots.
In the univariate analysis, we evaluated epidemiological variables, assessed at the time of diagnosis, such as age in years, ethnicity, sex and smoking and alcohol status, and clinical characteristics, such as tumor site, tumor stage and treatment. We did not incorporate any interaction terms in the first step in building a multivariable model for time to SPM occurrence. A multivariable proportional hazards model was built using the variables that had prognostic potential suggested by the univariate analysis (P , 0.25). Due to epidemiological and clinical considerations in building the model, age, sex and ethnicity were always retained in the main-effects and final multivariable model. We used a stepwise search strategy to build the multivariable models, for which a threshold level of 0.25 for the likelihood ratio test was used as a cutoff to determine whether a variable could be entered into, or removed from, the regression model. We assessed associations using hazard ratios (HRs) and their 95% confidence intervals (CIs) for a SPM development. The final fully adjusted Cox regression models included age, sex, ethnicity and smoking and alcohol status. For all analyses, statistical significance was set at P , 0.05, and all tests were two sided. The Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC) was used to perform all statistical analyses.
Results

Patient characteristics
The demographics, risk exposure and clinical variables for the 1282 patients were shown in Table I . We followed up these 1282 patients with a median follow-up time of 34.1 months (range 0-142.4 months). Overall, 1162 patients did not develop SPM, whereas 120 (9.4%) patients developed SPM. Of the 120 patients with SPM, 81 patients developed SPMs at tobacco-associated sites (44 SCCHN), 35 developed SPMs at other sites and four developed SPMs at both sites. Of the 44 patients with second SCCHN, 24 (55%) were synchronous SCCHN primaries. Of these 24 patients with synchronous SCCHN, two patients had bilateral oral cavity cancers, three had bilateral oropharyngeal cancers, one had bilateral hypopharyngeal cancers and the remainder had simultaneous cancers of more than one head and neck subsite.
In this cohort of 1282 patients, the mean age at diagnosis for the index SCCHN patients was 57.4 years (range: 18-94 years and median: 57 years), and the mean age of patients at index SCCHN who developed SPM was significantly older compared with the mean age of patients who did not develop SPM (60.8 years versus 57.1 years, p21 genetic polymorphisms and second malignancies respectively; P , 0.01). Although the participants in this study were predominantly male (76.1%), sex was not associated with SPM development (P 5 0.552). Compared with the SPM-free group, patients who developed SPM had similar characteristics regarding index smoking (P 5 0.128), alcohol drinking (P 5 0.352), cancer site (P 5 0.308), cancer stage (P 5 0.697) and treatment (P 5 0.887). However, the patients who developed SPM were more probably to be older (P , 0.001) and non-Hispanic whites (P 5 0.051) than the patients who did not develop SPM.
Association of p21 polymorphisms with risk of SPM after index SCCHN Table II showed distributions of p21 C98A and p21 C70T genotypes between the patients who developed SPM and the patients who did not and the associations with risk of SPM development. For the two p21 polymorphisms, the distribution of p21 C98A and p21 C70T genotypes was significantly different between patients who developed SPM and those who did not (P 5 0.010 for p21 C98A and P 5 0.0050 for p21 C70T). Additionally, patients who possessed the p21 98 CA/AA variant genotypes were at 1.8-fold increased risk to develop SPM as compared with those with the homozygous wildtype genotype after multivariate adjustment for age, sex, ethnicity, smoking and drinking (Table II) . Similarly, those who possess the p21 70 CT/TT variant genotypes were at 1.8-fold increased risk of SPM as compared with those with p21 70 CC genotype (Table II) . To evaluate the combined effect of both p21 polymorphisms together on risk of SPM, we combined the wild-type homozygous genotypes of the two polymorphisms into one group as a 'no variant' reference group and combined other variant genotypes including variant homozygous and heterozygous genotypes into another group, 'variant' group. We found that the distribution of the combined genotypes was significantly different between patients who developed SPM and those who remained SPM free (P 5 0.0014). Moreover, the patients with p21 variant genotypes of both polymorphisms experienced a significantly reduced SPM-free survival compared with patients with no p21 variant genotypes (log-rank, P 5 0.0016, Figure 1) . Furthermore, patients possessing either variant allele (p21 98 A or p21 70 T) had almost a 2-fold increased risk for SPM (HR 5 2.00, 95% CI 5 1.26-3.00) compared with patients with the combined p21 98 CC and p21 70 CC wild-type genotypes. Table III showed the association between the combined p21 genotypes and risk of SPM in each subgroup further stratified by age, sex, ethnicity, smoking/drinking status, index cancer site, index cancer stage, index cancer treatment and SPM type. When we used the combined no variant genotype group (p21 98 CC and p21 70 CC) as the reference, there was a .2-fold significantly increased SPM risk for those with any p21 variant genotypes among older patients, males, patients with early stage cancers and patients with cancers of nonoropharyngeal sites (Table III) . Additionally, a significantly elevated SPM risk associated with any p21 variant genotypes was found among non-Hispanic whites, smokers, drinkers and for those who received some DNA-damaging agent during the treatment of their index cancer (Table III) . Additionally, the p21 variant genotypes were associated with significantly increased risk of SPM, whether at tobaccoassociated SPM sites (HR 5 1.71, 95% CI 5 1.02-2.87) or other SPM sites (HR 5 2.32, 95% CI 5 1.07-5.05). After we performed the tests of heterogeneity of the stratified estimates, we found that there was a significant interaction effect between the combined variant genotypes of p21 polymorphisms and age, sex, ethnicity, smoking/ alcohol status, treatment and index cancer site on risk of SPM, and the Chi-squared test for differences in the distribution of p21 genotypes between the patients who developed SPM and the patients who did not. b Adjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking in a Cox model. Fig. 1 . Kaplan-Meier SPM-free survival curve stratified by combined p21 wild-type genotypes and variant genotypes.
Stratification analysis of the combined p21 genotypes with risk of SPM
interaction effect of the combined variant genotypes of p21 polymorphisms with index cancer stage on risk of SPM was only borderline statistically significant (Table III) .
Discussion
It is plausible that p21 polymorphisms might affect cancer risk, as p21 can be induced by p53 in response to DNA damage, to arrest cellular growth allowing for DNA repair (42) . Previous studies have evaluated the association of these p21 polymorphisms and risk of or survival from several types of cancer (38, (43) (44) (45) (46) , but none of these evaluated the association of these p21 polymorphisms and risk of SPM after index SCCHN. In the current study of 1282 patients with SCCHN, we found that patients with p21 98 CA/AA and p21 70 CT/TT variant genotypes had a significantly greater risk of developing SPM compared with patients with the p21 98 CC and p21 70 CC wild-type homozygous genotype, respectively, and the combined variant genotypes of the two polymorphisms had a moderately increased risk of SPM compared with the combined wild-type homogenous genotypes after multivariable adjustment. Additionally, the SPM risk associated with the combined variant genotypes was particularly more pronounced in several subgroups. Like other key cell cycle regulators, p21 plays an important role in regulating critical cellular activities, such as cell cycle control, DNA repair and apoptosis, and consequently could influence the efficiency of response to DNA damage and tumor development. To date, there is no known functional relevance of the p21 polymorphisms, but our study and others do suggest that the p21 C98A and p21 C70T polymorphisms have functional significance and are probably to contribute to genetic susceptibility to cancer (38, 47, 48) . The p21 C98A polymorphism causes a serine-to-arginine substitution in its zincfinger motif, which could alter the p21 protein's function (49) . Because p21 C70T polymorphism at exon 3 lies within the 3' untranslated region 20 nt downstream of the stop codon, it is more probably that the p21 C70T polymorphism may increase cancer risk by altering messenger RNA stability, thereby affecting intracellular levels of p21 protein. However, all these hypotheses remain to be tested in future studies.
One published SCCHN study examined the association between p21 C98A and p21 C70T and SCCHN risk in 42 patients and 110 controls (50) and found p21 polymorphisms in 9.1% of controls (10 of 110) and 21.4% of SCCHN patients (9 of 42), but the difference was not statistically significant, most probably due to the study with a small sample size. We have also previously reported that these p21 polymorphisms were associated with a significantly increased risk of SCCHN (38) . In the current study, we observed a nearly 1.8-fold increased risk of SPM for each of the two polymorphisms and an $2-fold increased risk of SPM for having either variant genotype.
A greater risk associated with the p21 variant genotypes in older (.57 years) subjects supports the implication of age as a risk factor for the development of SPM after index SCCHN (P , 0.001). We also found that the SPM risk associated with the combined variant genotypes reached the statistically significant level in men but not in women. This finding may be because that the men are more probably ever-smokers and less probably never-smokers than women in this study (P 5 0.002) and men with the combined p21 variant genotypes may be more sensitive to tobacco carcinogens. The finding of a greater risk in ever-smokers and ever-drinkers also suggests that the combined p21 variant genotypes may have an impact on cell cycle control that was induced by DNA damage caused by carcinogens in tobacco smoke and alcohol use. However, we found that the risk of SPM associated with the p21 variant genotypes was for SPM at both tobacco-associated sites and other sites.
Previous studies have reported that there is no significant association of SPM occurrence with clinical characteristics or treatment but, rather, with previous and continued exposure to tobacco or alcohol p21 genetic polymorphisms and second malignancies (7, 8) except one study demonstrating that radiotherapy for oral cancer may be a risk factor for SPMs (51) . However, in this study, we found that these p21 variant genotypes appeared to be risk factors for SPM in SCCHN patients whether they received radiation as part of their index cancer treatment (HR 5 1.7, 95% CI 5 1.0-2.7) or not (HR 5 2.6, 95% CI 5 1.0-7.1), even after controlling for smoking and alcohol status. When we stratified clinical characteristics for further analysis, we found a significant association of the p21 variant genotypes with risk of SPM within several subgroups, which suggested that genetic factors, within the context of previous or continued exposure to smoking and alcohol, as well as clinical characteristics may affect the risk of SPM after index SCCHN (52, 53) . For instance, we found that the SPM risk associated with the p21 variant genotypes was greater in patients with non-oropharyngeal index cancer than in those with oropharyngeal cancers. This may be because SPM that arise in patients with index non-oropharyngeal SCCHN may have a different etiology in relation to environmental risk factors and genetic susceptibility than those arising in patients with index oropharyngeal cancer. Our previous studies suggests that among SCCHN sites, most of squamous cell carcinomas of the oropharynx are more probably caused by human papillomavirus type 16, whereas squamous cell carcinomas of the oral cavity and larynx are more probably driven by smoking and alcohol use (54) . While the risk of tobacco-or alcohol-induced SPM after index non-oropharyngeal carcinoma may be modified by p21 genotypes, these genotypes may play an even greater role in SPM of non-oropharyngeal cancers arising in eversmokers and ever-drinker. However, larger studies are needed to validate these findings. This current study is a large and well-characterized cohort in SCCHN patients treated at a multidisciplinary cancer center with significant experience treating SCCHN, but our findings may have been affected by several limitations. Although this patient cohort included multiple ethnicities, 84.5% of patients were non-Hispanic whites and these findings may not be relevant to SPM risk after index SCCHN in other populations. In addition, we collected prospectively demographics, exposure and clinical data for the cohort, whereas we collected retrospectively clinical outcomes including SPM under a no strictly defined screening or follow-up regimen. Furthermore, our high prevalence of never-smokers, most SCCHN patients with late stage and our strict criteria in defining SPM in this study may result in limited follow-up time and less opportunity to develop SPM. The rate of SPM in this study was also underestimated because the relative short follow-up time in this study may have limited opportunity for patients with index SCCHN to develop SPM. The smaller number of SPM also limits statistical power, particularly in subgroup analyses. Finally, due to the retrospective nature of the original study design, we neither collected information on human papillomavirus status, one of the major risk factors for oropharyngeal cancer, nor have data on continued smoking behavior after index SCCHN diagnosis. The estimates of association may be biased due to the lack of this information in this study. Therefore, to minimize the biases in association from these confounding factors, our future studies on the association between genetic polymorphisms and risk of SPM should take human papillomavirus and smoking behavior into account once this information becomes available.
In conclusion, the current investigation supports a significant role of p21 C98A and p21 C70T polymorphisms in the development of SPM after index SCCHN. These two polymorphisms appeared to contribute jointly to a moderately increased risk of SPM after index SCCHN. Due to complexity with multiple genetic and environmental factors in the development of SPM, the pathway-oriented studies of carcinogen metabolism, DNA repair, cell cycle control and apoptosis systems are needed to more comprehensively evaluate associations between genetic variants and risk of SPM after index SCCHN. 
